Engineering antibodies for imaging and therapy

Current Opinion in Biotechnology

Volumn 8, Issue 4, 1997, Pages 449-454

  Carter, Paul ^a   Merchant, A Margaret ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOLIPOSOME; IMMUNOTOXIN;

ANTIBODY AFFINITY; ANTIGEN BINDING; BIOTECHNOLOGY; CANCER IMMUNOTHERAPY; DIAGNOSTIC IMAGING; DRUG TARGETING; GENETIC ENGINEERING; IMMUNIZATION; IMMUNOGENICITY; ISOTOPE LABELING; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; TRANSGENIC MOUSE; TUMOR; TUMOR VASCULARIZATION;

MUS MUSCULUS;

EID: 0030762401     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0958-1669(97)80067-5     Document Type: Article

References (54)

1. Nilsson B: Antibody engineering. Curr Opin Struct Biol 1995, 5:450-456.
2. Kelley RF: Engineering therapeutic antibodies. In Protein engineering: principles and practice. Edited by Cleland JL, Craik CS. New York: Wiley-Liss; 1996:399-434.
3. Adair JR, Bright SM: Progress with humanized antibodies - an update. Exp Opin Invest Drugs 1995, 4:863-870.
4. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR: Making antibodies by phage display technology. Ann Rev Immunol 1994, 12:433-455.
5. Neuberger M, Brüiggemann M: Mice perform a human repertoire. Nature 1997, 386:25-26.
6. Ghetie MA, Vitetta ES: Recent developments in immunotoxin therapy. Curr Opin Immunol 1994, 6:707-714.
7. Holliger P, Winter G: Engineering bispecific antibodies. Curr Opin Biotechnol 1993, 4:446-449.
8. Carter P, Ridgway J, Zhu Z: Toward the production of bispecific antibody fragments for clinical applications. J Hematotherapy 1995, 4:463-470.
9. Ashkenazi A, Chamow S: Immunoadhesins as research tools and therapeutic agents. Curr Opin Immunol 1997, 9:195-200.
10. Von Mehren M, Weiner LM: Monoclonal antibody-based therapy. Curr Opin Oncol 1996, 8:493-498.
11. Reiter Y, Brinkmann U, Lee B, Pastan I: Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilired Fv fragments. Nat Biotech 1996, 14:1239-1245.
12. Melton RG, Sherwood RF: Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 1996, 88:153-165.
13. Bagshawe KD: Antibody-directed enzyme prodrug therapy: a review. Drug Dev Res 1995, 34:220-230.
14. Plückthun A, Krebber A, Krebber C, Horn U, Knüpfer U, Wenderoth R, Nieba L, Proba K, Riesenberg D: Producing antibodies in Escherichia coli: from PCR to fermentation. In Antibody Engineering: a Practical Approach. Edited by Hoogenboom H, McCafferty J, Chiswell D. Oxford: IRL Press; 1996:203-252.
15. Chen SY, Marasco WA: Novel genetic immunotoxins and intracellular antibodies for cancer therapy. Semin Oncol 1996, 23:148-153.
16. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744. This is the first report of objective responses in solid tumors treated with a humanized antibody.
17. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann R, Jones PT, Low NM, Allison TJ et al.: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994, 13:3245-3260.
18. 10) natural human scFv phage library is constructed and used for the rapid identification of nanomolar and subnanomolar affinity antibodies to haptens and protein antigens.
19. Fishwild DM, O'Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, Jones D, Kay RM, Higgins KM, Schramm SR, Lonberg N: High avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996, 14:845-851. Human antibodies with high apparent affinities are obtained following immunization of transgenic mice containing a small fraction of the human immunoglobulin gene repertoire.
20. Mendez MJ, Green LL, Corvalan JRF, Jia XC, Maynard-Currie CE, Yang XD, Gallo ML, Louie DM, Lee DV, Erickson KL et al.: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997, 15:146-156. Transgenic mice containing a significant fraction of the human immunoglobulin gene loci are immunized and shown to produce high affinity human antibodies to several different human antigens.
21. Yang W-P, Green K, Pinz-Sweeney S, Briones, AT, Burton DR, Barbas CF III: CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 1995, 254:392-403.
22. d) of a human antibody from 16 nM to 13 pM. The affinity enhancement strategies described together with those in [21] will probably be broadly useful in engineering antibodies for human therapy.
23. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I: Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996, 2:350-353.
24. Rybak SM, Hoogenboom HR, Meade HM, Raus JC, Schwartz D, Youle RJ: Humanization of immunotoxins. Proc Natl Acad Sci USA 1992, 89:3165-3169.
25. Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM: Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 1996, 35:545-553.
26. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 1993, 53:3336-3342.
27. Chari RVJ, Martell BA, Gross JL, Cook SB, Shah SA, Blattler WA, McKenzie SJ, Goldmacher VS: Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992, 52:127-131.
28. Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM et al.: Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996, 93:8618-8623. An antibody-maytansinoid conjugate is found to cure mice bearing small tumor xenografts and to give complete regressions for mice with large tumors or for mice in which only a small fraction of the tumor cells is antigen positive.
29. Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993, 90:8996-9000.
30. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997, 275:547-550. A bispecific antibody is used to deliver tissue factor to tumor vasculature, triggering local thrombosis and complete tumor regression in some mice.
31. Lasic DD, Papahadjopoulos D: Liposomes revisited. Science 1995, 267:1275-1276.
32. Park JW, Hong K, Carter P, Asgari H, Guo LY, Keller GA, Wirth C, Shalaby R, Kotts C, Wood WI et al.: Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995, 92:1327-1331.
33. HER2 immunoliposomes is shown to increase concomitantly with the surface density of the Fab′ fragment used for targeting, reaching plateaus at approximately 40 Fab′/liposome for binding and 10-15 Fab′/liposome for internalization.
34. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WLT, Rowland AM, Kotts CE, Carver ME et al.: High level Escherichia coli expression and production of a bivalent humanized antibody fragment Bio-Technology 1992, 10:163-167.
35. Laukkanen ML, Teeri TT, Keinanen K: Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. Protein Eng 1993 6:449-454.
36. Laukkanen ML, Alfthan K, Keinanen K: Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. Biochemistry 1994, 33:11664-11670.
37. Huwyler J, Wu D, Pardridge WM: Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996, 93:14164-14169.
38. Holliger P, Prospero T, Winter G: 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993, 90:6444-6448.
39. •].
40. Zhu Z, Presta LG, Zapata G, Carter P: Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997, 6:781-788.
41. •], demonstrates that diabodies can be used to retarget cytotoxic T cells to kill tumor cells in vitro.
42. McGuinness BT, Walter G, FitzGerald K, Schuler P, Mahoney W, Duncan AR, Hoogenboom H: Phage diabody repertoires for selection of large numbers of bispecific antibody fragments. Nat Biotechnol 1996, 14:1149-1154.
43. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature 1983, 305:537-540.
44. Suresh MR, Cuello AC, Milstein C: Bispecific monoclonal antibodies from hybrid hydridomas. Methods Enzymol 1986, 121:210-228.
45. H3 domains for heavy chain heterodimerization. Protein Eng 1996, 9:617-621. A rational design strategy is used to direct the assembly of antibody heavy chains. This technology is anticipated to be broadly useful in the production of Fc-containing bifunctional therapeutics.
46. H3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996, 56:3055-3061. A designer bivalent antibody fragment, the minibody, is shown to be a highly effective imaging agent in tumor-bearing mice. Thus the minibody is a very promising candidate for clinical radioimmunoimaging trials.
47. George AJ, Jamar F, Tai MS, Heelan BT, Adams GP, McCartney JE, Houston LL, Weiner LM, Oppermann H, Peters AM, Huston JS: Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci 1995, 92:8358-8362.
48. 32P]-ATP. Nat Biotechnol 1996, 14:485-490. An scFv fragment is appended with a recognition site for casein kinase, permitting site-specific radiophosphorylation in vitro. Site-specific labeling is superior to traditional 'random' labeling in that the resultant molecular population is much more homogeneous with well-defined radionuclide stoichiometry and is likely close to full immunoreactivity.
49. Sheriff S, Constantine KL: Redefining the minimal antigen-binding fragment Nat Struct Biol 1996, 3:733-736.
50. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G: Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989, 341:544-546.
51. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R: Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
52. H domains as small recognition units. Bio-Technology 1995, 13:475-479.
53. H antibodies from camels.
54. H-lysozyme complex revealed that the contacts with antigen were dominated by the heavy chain CDR3.